查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197414

生命科学工具市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Life Science Tools Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

生命科学工具市场预计在预测期内的复合年增长率为 7.5%。

在全球范围内，COVID-19 大流行对生命科学工具市场的增长产生了积极影响，导致诊断技术快速发展，监管审批迅速，每个国家的分销量都有所增加。 不同的诊断程序对于传染病的检测始终是必不可少的。 目前正在进行几种分子和免疫测定来检测 COVID-19。 然而，在大流行之后，生命科学行业正在积极研究如何为全球大流行的意外负担做准备。 例如，2022 年 9 月，世卫组织发布了负责任地使用生命科学工具的指导框架。 该框架将指导领导者降低风险并安全地管理具有明显好处但可能被滥用以伤害人类、其他动物、农业和环境以及其他相关方的双重用途研究。 因此，随着对生命科学的日益关注，预计未来几年所研究的市场将显着增长。

基因组技术在全球范围内越来越多地被用于了解各种疾病，并有助于开发新的诊断测试和程序，从而推动市场的增长。 例如，2022 年 9 月，Becton, Dickinson, and Company (BD) 和 CerTest Biotec 开始在美国和全球市场商业分销一种新的猴痘病毒分子聚合□链反应 (PCR) 检测方法。 该公司表示，这种 PCR 检测仅用于研究目的。 随着此类新试剂的推出，市场有望在预测期内实现强劲增长。

此外，与测序技术、色谱法、质谱法等相关的技术进步增加了医院、实验室和诊断实验室对这些工具的采用。 根据世卫组织 2021 年情况说明书，680,000 人死于与艾滋病毒相关的原因，150 万人感染了艾滋病毒。 因此，高患者数量将推动对治疗的需求，进一步增加生命科学工具的使用，以识别、诊断和监测某些传染病的进展。

此外，对各种传染病诊断测试的需求不断增长，将刺激用于诊断目标人群的生命科学工具的发展，并在预测期内推动整个市场的增长。看来。

生命科学工具的市场趋势

分离技术生命科学工具预计在预测期内实现健康增长

分离技术领域的主要驱动力包括增加对药物研发的投资以及生命科学行业对色谱技术的更多采用。

在全球范围内，COVID-19 的爆发对生命科学设备市场产生了积极影响。 由于 COVID-19 爆发引起的疾病增加，后续的研发活动有所增加。 增加对药物发现的投资预计将推动分离技术领域的增长。 例如，2022 年 5 月，Cipla 宣布在印度实现 COVID-19 PCR 试剂盒的商业化。 这种实时 RT-PCR 检测试剂盒已在印度医学研究委员会 (ICMR) 认可的中心进行了验证。

分离技术，包括免疫沉淀、色谱技术和自动纯化系统，可用于诊断和治疗 COVID-19。 例如，根据 2021 年印度医学研究杂誌，在印度北部的一家三级护理教学医院进行了一项研究，以评估基于快速免疫测定的色谱测试在 COVID-19 诊断中的作用。 因此，基于免疫测定的快速色谱测试可以帮助快速检测、隔离和治疗 COVID-19 患者。

此外，与色谱技术相关的多项优势使其在多个行业得到广泛采用。 减少对大型色谱柱的需求等好处可提高生产过程的效率和生产率。 因此，每个部门越来越多地采用多种分离技术将增加对生命科学工具的需求并推动该部门的增长。

全球传染病流行推动了生命科学工具的采用。 例如，根据 WHO 2021 Factsheet，2021 年将有 150 万人死于结核病，全球估计有 1000 万人患有结核病。 近年来，它一直在稳步下降。 但是，它仍然处于相当高的标准。

因此，上述因素预计将在预测期内推动细分市场的增长。

预计在预测期内北美将占据重要的市场份额

推动北美市场增长的主要因素是基因组手术数量的增加、研发支出的增加、众多大公司的存在、生物製药公司的采用率增加、产品发布和技术进步等。

美国 COVID-19 的爆发导致诊断程序的增加，从而导致市场增长。 因此，事实证明，使用新技术进行的诊断有利于 COVID-19 的管理，从而推动生命科学设备市场的增长。

美国生物製药行业正在显着扩张，包括合成疫苗、纳米抗体、rDNA、融合蛋白、免疫偶联物、可溶性受体和免疫疗法等新产品类型。 预计製药和生物製药行业增加对生命科学工具、研究和学术的研发投资将推动市场。

例如，根据美国研究和製药製造商协会 (PhRMA) 的数据，美国生物製药行业是新药开发领域的世界领先者之一。 预计 2021 年生物製药和製药行业整体的研发 (R&D) 投资将达到约 911 亿美元，而上一年约为 830 亿美元。

此外，预计在预测期内，越来越多地采用新型药物输送系统和越来越多的传染病患者将推动该地区的生命科学工具市场。

生命科学工具市场竞争对手分析

生命科学工具市场的竞争很低。 市场参与者正在采用产品批准和发布、收购、合作伙伴关係和协议等策略。 一些市场参与者包括 Becton、Dickinson and Company、Agilent Technologies、Illumina Inc.、Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd、Merck KGaA、GE Healthcare、Bruker QIAGEN。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 对生物製药的需求不断增长，对生命科学研究的资助不断增加
    • 目标传染病和遗传病的发病率增加
  • 市场製约因素
    • 设备成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 设备
    • 消耗品
    • 服务
  • 按技术
    • PCR 和 qPCR
    • 桑格序列
    • 分离技术
    • 流式细胞术
    • 核酸微阵列
    • 质谱
    • 其他技术
  • 通过申请
    • 蛋白质组学技术
    • 基因组技术
    • 细胞生物学技术
    • 其他应用
  • 最终用户
    • 研究所
    • 诊断研究所
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Becton, Dickinson and Company
    • Agilent Technologies Inc.
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories Inc.
    • Merck KGaA
    • GE Healthcare
    • Bruker Corporation
    • Qiagen NV
    • Danaher Corporation
    • Abbott Laboratories Inc.

第7章 市场机会今后动向

简介目录
Product Code: 70668

The life science tools market is expected to record a CAGR of 7.5% during the forecast period.

Globally, the COVID-19 pandemic positively impacted the growth of the life science tools market with the rapid development of diagnostics, fast-tracked regulatory clearances, and increased distribution in various countries to help curb the spread of the virus. Various diagnostic procedures have always been essential in the detection of infectious diseases. Currently, several molecular assays and immunoassays are in place to detect COVID-19. However, in the aftermath of the pandemic, there has been increased research in the life sciences industry to prepare for any unexpected global pandemic burden. For instance, in September 2022, the WHO issued a guidance framework for the responsible use of life science tools. The Framework calls on leaders and other stakeholders to mitigate risks and safely govern dual-use research, which has a clear benefit but can be misused to harm humans, other animals, agriculture, and the environment. Hence, with the increasing focus on life science, the market studied is expected to grow significantly in the coming years.

Genomic technologies are increasingly being used globally to understand and contribute to developing new diagnostic tests or procedures for various diseases, boosting the market's growth. For instance, in September 2022, Becton, Dickinson, and Company (BD) and CerTest Biotec commercially launched their new molecular polymerase chain reaction (PCR) assay for the monkeypox virus for the US and global markets. The company has stated that this PCR assay will only be available for research purposes. With such new launches, the market is expected to witness strong growth over the forecast period.

Furthermore, technological advancements associated with sequencing technologies, chromatography methods, mass spectrometry, and other products led to the increasing adoption of these tools in hospitals, research labs, and diagnostic laboratories. According to the WHO 2021 Factsheet, 680,000 people died from HIV-related causes, and 1.5 million people acquired HIV. Thus, a high patient population will boost the demand for treatment and further increase the use of life sciences tools for identifying, diagnosing, and monitoring the progression of several infectious diseases.

Furthermore, the rising demand for diagnostic tests for a variety of infectious diseases will spur the development of life science tools for diagnosing the target population, propelling overall market growth over the forecast period.

Life Science Tools Market Trends

Life Science Tools in Separation Technologies is Estimated to Witness a Healthy Growth Rate Over the Forecast Period

The major factors driving the separation technologies segment include growing investments in pharmaceutical R&D and the increasing adoption of chromatography technologies by the life sciences industries.

Globally, the COVID-19 pandemic positively impacted the life science instruments market. The outbreak of COVID-19 resulted in an increased number of diseases, which led to a subsequent increase in research and development activities. Increasing investment in drug discovery is expected to fuel the growth of the separation technology segment. For example, in May 2022, Cipla announced the commercialization of its COVID-19 PCR kit in India. The real-time RT-PCR test kit has been validated by an Indian Council of Medical Research (ICMR)-approved center.

Separation technologies include immunoprecipitation, chromatographic techniques, automated purification systems, and others that aid in diagnosing and treating COVID-19. For example, according to the Indian Journal of Medical Research 2021, a study was conducted in a tertiary care teaching hospital in northern India to assess a rapid immunoassay-based chromatographic test in the diagnosis of COVID-19. The results of the study showed that immunoassay-based rapid chromatographic tests can help in the rapid detection, isolation, and treatment of patients with COVID-19.

In addition, this technology is widely adopted by several industries due to several advantages associated with chromatography technology. Benefits such as reducing the need for large columns increase the efficiency and productivity of the production process. Thus, increased adoption of multiple separation technologies across sectors would increase the demand for life science tools and drive segment growth.

The increasing prevalence of infectious diseases worldwide will encourage the adoption of life science tools. For example, according to the WHO 2021 Factsheet, 1.5 million people died of tuberculosis in 2021, and an estimated 10 million people contracted tuberculosis (TB) worldwide. It has been steadily declining in recent years. However, it is still at a much higher level.

Thus, the above-mentioned factors are expected to drive segment growth over the forecast period.

North America is Expected to Hold a Significant Market Share over the Forecast Period

The major factors driving market growth in North America include the rising number of genomic procedures, increasing research and development expenditure, the presence of a large number of major players, growing adoption among biopharmaceutical companies, product launches, and technological advancements.

With the outbreak of COVID-19 in the United States, there has been an increase in the number of diagnostic procedures, leading to market growth. Thus, diagnostic procedures with new technologies have proven beneficial in managing COVID-19 and are driving the growth of the life sciences instruments market.

The biopharmaceutical industry in the United States has expanded significantly to include new product types such as synthetic vaccines, nanoantibodies, rDNA, fusion proteins, immunoconjugates, soluble receptors, and immunotherapeutics. The pharmaceutical and biopharmaceutical industries' increased R&D investment in life science tools, research, and academics is expected to drive the market.

For example, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical industry is one of the world leaders in new drug development. The entire biopharmaceutical and pharmaceutical industry invested an estimated USD 91.1 billion in research and development (R&D) in 2021, compared to about USD 83 billion invested in research and development (R&D) in the previous year.​​

Furthermore, the increasing adoption of novel drug delivery systems and the rising prevalence of infectious disease cases are expected to fuel the life science tools market in the region over the forecast period.

Life Science Tools Market Competitor Analysis

The life science tools market is moderately competitive. The market players adopted strategies such as product approval and launches, acquisitions, partnerships, and agreements. Some of the market players include Becton, Dickinson and Company, Agilent Technologies, Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, GE Healthcare, and Bruker QIAGEN.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Demand for Biopharmaceuticals and Increasing Funding for Life Science Research
    • 4.2.2 Rising Incidence of Target Infectious Diseases and Genetic Disorders
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Instruments
    • 5.1.2 Consumables
    • 5.1.3 Services
  • 5.2 By Technology
    • 5.2.1 PCR and qPCR
    • 5.2.2 Sanger Sequencing
    • 5.2.3 Separation Technologies
    • 5.2.4 Flow Cytometry
    • 5.2.5 Nucleic Acid Microarray
    • 5.2.6 Mass Spectrometry
    • 5.2.7 Other Technologies
  • 5.3 By Application
    • 5.3.1 Proteomics Technology
    • 5.3.2 Genomic Technology
    • 5.3.3 Cell Biology Technology
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Research Laboratories
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Illumina Inc.
    • 6.1.4 Thermo Fisher Scientific Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Bio-Rad Laboratories Inc.
    • 6.1.7 Merck KGaA
    • 6.1.8 GE Healthcare
    • 6.1.9 Bruker Corporation
    • 6.1.10 Qiagen NV
    • 6.1.11 Danaher Corporation
    • 6.1.12 Abbott Laboratories Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS